JP2011522540A - 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 - Google Patents

非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 Download PDF

Info

Publication number
JP2011522540A
JP2011522540A JP2011512634A JP2011512634A JP2011522540A JP 2011522540 A JP2011522540 A JP 2011522540A JP 2011512634 A JP2011512634 A JP 2011512634A JP 2011512634 A JP2011512634 A JP 2011512634A JP 2011522540 A JP2011522540 A JP 2011522540A
Authority
JP
Japan
Prior art keywords
cells
cell
differentiation
vector
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522540A5 (https=
Inventor
アマンダ マック，
ジェームス トムソン，
Original Assignee
セルラー ダイナミクス インターナショナル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40977641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011522540(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セルラー ダイナミクス インターナショナル， インコーポレイテッド filed Critical セルラー ダイナミクス インターナショナル， インコーポレイテッド
Publication of JP2011522540A publication Critical patent/JP2011522540A/ja
Publication of JP2011522540A5 publication Critical patent/JP2011522540A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011512634A 2008-06-04 2009-06-04 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 Pending JP2011522540A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5885808P 2008-06-04 2008-06-04
US61/058,858 2008-06-04
US16058409P 2009-03-16 2009-03-16
US61/160,584 2009-03-16
PCT/US2009/046209 WO2009149233A1 (en) 2008-06-04 2009-06-04 Methods for the production of ips cells using non-viral approach

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014121146A Division JP2014209912A (ja) 2008-06-04 2014-06-12 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法

Publications (2)

Publication Number Publication Date
JP2011522540A true JP2011522540A (ja) 2011-08-04
JP2011522540A5 JP2011522540A5 (https=) 2012-05-31

Family

ID=40977641

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011512634A Pending JP2011522540A (ja) 2008-06-04 2009-06-04 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
JP2014121146A Withdrawn JP2014209912A (ja) 2008-06-04 2014-06-12 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
JP2017132684A Pending JP2018007667A (ja) 2008-06-04 2017-07-06 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
JP2017132685A Pending JP2018019684A (ja) 2008-06-04 2017-07-06 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
JP2020070205A Pending JP2020115881A (ja) 2008-06-04 2020-04-09 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014121146A Withdrawn JP2014209912A (ja) 2008-06-04 2014-06-12 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
JP2017132684A Pending JP2018007667A (ja) 2008-06-04 2017-07-06 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
JP2017132685A Pending JP2018019684A (ja) 2008-06-04 2017-07-06 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
JP2020070205A Pending JP2020115881A (ja) 2008-06-04 2020-04-09 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法

Country Status (10)

Country Link
US (4) US8546140B2 (https=)
EP (4) EP3279314A1 (https=)
JP (5) JP2011522540A (https=)
KR (2) KR101871192B1 (https=)
AU (1) AU2009256202B2 (https=)
CA (2) CA2954948A1 (https=)
DK (1) DK2297307T3 (https=)
ES (1) ES2587395T3 (https=)
IL (1) IL209740A (https=)
WO (1) WO2009149233A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013176233A1 (ja) * 2012-05-23 2013-11-28 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
US9404124B2 (en) 2009-08-07 2016-08-02 Kyoto University Method of producing induced pluripotent stem cells using inhibitors of P53
JP2019500910A (ja) * 2016-01-12 2019-01-17 ロンザ ウォカーズビル インコーポレーティッド ベクターを含まない人工多能性幹細胞を作製するための方法およびベクター
US10260048B2 (en) 2010-06-15 2019-04-16 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8048999B2 (en) * 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
JP5813321B2 (ja) 2007-03-23 2015-11-17 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US20100279404A1 (en) * 2008-05-02 2010-11-04 Shinya Yamanaka Method of nuclear reprogramming
EP3279314A1 (en) 2008-06-04 2018-02-07 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
EP3231869A1 (en) * 2008-06-13 2017-10-18 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
CA2734128A1 (en) 2008-08-12 2010-02-18 Cellular Dynamics International, Inc. Methods for the production of ips cells
DK2356221T3 (en) * 2008-10-24 2019-02-18 Wisconsin Alumni Res Found Pluripotent stem cells obtained by non-viral reprogramming
JP2012508591A (ja) * 2008-11-14 2012-04-12 ライフ テクノロジーズ コーポレーション 細胞を操作するための組成物および方法
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EP2421957B1 (en) 2009-04-22 2020-11-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
WO2010141801A2 (en) 2009-06-05 2010-12-09 Cellular Dynamics International, Inc. Reprogramming t cells and hematophietic cells
EP2483395B1 (en) 2009-09-30 2016-12-07 Agency For Science, Technology And Research A nuclear receptor and mutant thereof and the use of the same in the reprogramming of cells
WO2011056971A2 (en) * 2009-11-04 2011-05-12 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
WO2011119942A1 (en) * 2010-03-25 2011-09-29 Vistagen Therapeutics, Inc. Induction of ips cells using transient episomal vectors
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
EP2582793B1 (en) 2010-06-15 2017-09-06 Cellular Dynamics International, Inc. A compendium of ready-built stem cell models for interrogation of biological response
EP2582792B1 (en) 2010-06-18 2018-10-31 FUJIFILM Cellular Dynamics, Inc. Cardiomyocyte medium with dialyzed serum
CA2806858C (en) 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
WO2012054935A2 (en) * 2010-10-22 2012-04-26 Salk Institute For Biological Studies Formation of hematopoietic progenitor cells from mesenchymal stem cells
CA2826386C (en) 2011-02-08 2020-04-28 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
US9228204B2 (en) 2011-02-14 2016-01-05 University Of Utah Research Foundation Constructs for making induced pluripotent stem cells
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
WO2012159079A1 (en) 2011-05-18 2012-11-22 The Parkinson's Institute Assay to determine lrrk2 activity in parkinson's disease
JP2014520551A (ja) * 2011-07-11 2014-08-25 セルラー ダイナミクス インターナショナル， インコーポレイテッド 細胞のリプログラミング方法およびゲノムの改変方法
WO2013022022A1 (ja) * 2011-08-08 2013-02-14 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
CN109456932A (zh) 2011-10-17 2019-03-12 米纳瓦生物技术公司 用于干细胞增殖和诱导的培养基
AU2012347919B2 (en) 2011-12-05 2017-02-02 Factor Bioscience Inc. Methods and products for transfecting cells
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
JP5920741B2 (ja) 2012-03-15 2016-05-18 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
US20150064734A1 (en) 2012-03-21 2015-03-05 Kyoto University Method for screening therapeutic and/or prophylactic agents for alzheimer's disease
JP6112733B2 (ja) 2012-04-06 2017-04-12 国立大学法人京都大学 エリスロポエチン産生細胞の誘導方法
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
EP2863026A4 (en) 2012-04-27 2016-03-02 Hino Motors Ltd BURNER AND FILTER RENEWAL DEVICE
US9175263B2 (en) 2012-08-22 2015-11-03 Biotime, Inc. Methods and compositions for targeting progenitor cell lines
US9382531B2 (en) 2012-10-22 2016-07-05 Wisconsin Alumni Research Foundation Induction of hemogenic endothelium from pluripotent stem cells
KR102121086B1 (ko) 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
AU2014248167B2 (en) 2013-04-03 2019-10-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
WO2014170549A1 (en) * 2013-04-16 2014-10-23 Glykos Finland Oy A method for generating induced pluripotent stem cells
EP3888640B1 (en) 2013-06-05 2025-09-17 Reverse Bioengineering, Inc. Compositions and methods for induced tissue regeneration in mammalian species
RU2016100232A (ru) 2013-06-14 2017-07-17 Дзе Юниверсити Оф Квинсленд Почечные клетки-предшественники
CN103333918B (zh) * 2013-06-19 2015-12-02 中山大学 一种提高猪克隆胚胎体外发育效率的方法
US10738323B2 (en) 2013-07-12 2020-08-11 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
JP6536871B2 (ja) 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
US9988605B2 (en) 2013-12-11 2018-06-05 Korea Advanced Institute Of Science And Technology Method for preparing endocrine aggregate of insulin-producing beta cells from human pluripotent stem cells
EP3099801B1 (en) 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
KR20200138445A (ko) 2014-04-24 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
EP3584312A1 (en) * 2014-06-27 2019-12-25 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus e4orf1, and methods of making and using the same
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
AU2015305515B2 (en) 2014-08-19 2020-12-03 FUJIFILM Cellular Dynamics, Inc. Neural networks formed from cells derived from pluripotent stem cells
EP3207122B1 (en) 2014-10-14 2019-05-08 FUJIFILM Cellular Dynamics, Inc. Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures
US9828634B2 (en) 2015-01-22 2017-11-28 Regenerative Medical Solutions, Inc. Markers for differentiation of stem cells into differentiated cell populations
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
AU2016318774B2 (en) 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
DK3347456T3 (da) 2015-09-08 2024-02-19 Us Health Fremgangsmåde til reproducerbar differentiering af retinale pigmentepitelceller af klinisk kvalitet
US10947502B2 (en) 2015-10-20 2021-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
CN108779435B (zh) 2015-12-07 2022-05-03 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
EP3455346A1 (en) 2016-05-12 2019-03-20 Erasmus University Medical Center Rotterdam A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
AU2017290805B2 (en) 2016-07-01 2023-11-16 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
KR102625865B1 (ko) 2016-08-16 2024-01-16 후지필름 셀룰러 다이내믹스, 인코포레이티드 만능 세포를 분화시키는 방법
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
US11268950B2 (en) 2016-09-28 2022-03-08 Organovo, Inc. Use of engineered renal tissues in assays
JP7248571B2 (ja) 2016-10-05 2023-03-29 フジフィルム セルラー ダイナミクス，インコーポレイテッド ＭｅＣＰ２が破壊された誘導多能性幹細胞からの成熟系列の生成
JP7222900B2 (ja) 2016-11-09 2023-02-15 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ 細胞療法および創薬のための３ｄ血管化ヒト眼組織
SG11201909331UA (en) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
JP2020535834A (ja) 2017-10-03 2020-12-10 エスディーエフ バイオファーマ インコーポレイテッド 遺伝子修飾されたベータ細胞による糖尿病の治療
JP7554670B2 (ja) 2017-10-11 2024-09-20 フェイト セラピューティクス，インコーポレイテッド 一時的かつ一過性プラスミドベクター発現システムを用いる細胞のリプログラミング
JP7550647B2 (ja) 2018-02-14 2024-09-20 アントレラ セラピューティクス インコーポレイテッド Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用
GB201805683D0 (en) * 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
JP2021521792A (ja) 2018-04-20 2021-08-30 フジフィルム セルラー ダイナミクス，インコーポレイテッド 眼球細胞の分化方法及びその使用
IL281470B2 (en) * 2018-09-28 2025-08-01 Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
SG11202104401RA (en) 2018-11-19 2021-05-28 The United States Of America As Represented By The Secretary Biodegradable tissue replacement implant and its use
MX2021006208A (es) 2018-11-28 2021-10-01 Univ Texas Edición por multiplexación del genoma de células inmunitarias para mejorar la funcionalidad y resistencia al entorno supresor.
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
WO2020237104A1 (en) * 2019-05-23 2020-11-26 The Mclean Hospital Corporation Autologous cell replacement therapy for parkinson's disease
US12410401B2 (en) 2019-06-06 2025-09-09 Wisconsin Alumni Research Foundation (Warf) Generation of functional neutrophils and macrophages from induced pluripotent stem cells in chemically defined conditions using transient expression of ETV2
CA3145425A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
JP7058431B2 (ja) 2019-12-12 2022-04-22 国立大学法人千葉大学 巨核球および血小板を含む凍結乾燥製剤
US20230201267A1 (en) 2020-05-29 2023-06-29 FUJIFILM Cellular Dynamics, Inc. Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
BR112022024064A2 (pt) 2020-05-29 2023-01-31 Fujifilm Cellular Dynamics Inc Bicamada de epitélio pigmentado da retina e fotorreceptores e uso dos mesmos
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
WO2022075384A1 (ja) 2020-10-07 2022-04-14 マイキャン・テクノロジーズ株式会社 コロナウイルス感染性細胞及びその調製方法
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230159550A (ko) * 2021-03-25 2023-11-21 블루록 테라퓨틱스 엘피 유도 만능 줄기 세포 수득 방법
WO2022216624A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
BR112023018844A2 (pt) 2021-04-07 2023-10-10 Century Therapeutics Inc Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
JP2024514522A (ja) 2021-04-07 2024-04-02 センチュリー セラピューティクス，インコーポレイテッド 遺伝子導入ベクターおよび細胞を操作する方法
WO2022216911A1 (en) 2021-04-07 2022-10-13 FUJIFILM Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
CN117479952A (zh) 2021-04-07 2024-01-30 世纪治疗股份有限公司 用于嵌合抗原受体细胞的组合的人工细胞死亡/报告系统多肽及其用途
KR20240011831A (ko) 2021-05-26 2024-01-26 후지필름 셀룰러 다이내믹스, 인코포레이티드 만능 줄기 세포에서 유전자의 신속한 사일런싱을 방지하기 위한 방법
EP4346928B1 (en) 2021-05-28 2026-01-14 The United States of America, as represented by The Secretary, Department of Health and Human Services Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells
CA3220602A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
CN118159646A (zh) 2021-09-13 2024-06-07 富士胶片细胞动力公司 产生定向心脏祖细胞的方法
CA3235390A1 (en) 2021-10-29 2023-05-04 Deepika Rajesh Dopaminergic neurons comprising mutations and methods of use thereof
AU2022423987A1 (en) 2021-12-29 2024-07-11 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
KR20250067762A (ko) * 2022-04-08 2025-05-15 뉴욕 스템 셀 파운데이션, 인코포레이티드 iPSC의 생산 방법
EP4519319A1 (en) 2022-05-04 2025-03-12 Century Therapeutics, Inc. Cells engineered with an hla-e and hla-g transgene
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
JP2025522360A (ja) 2022-06-08 2025-07-15 センチュリー セラピューティクス，インコーポレイテッド Ｃｄ１６変異体およびｎｋｇ２ｄを発現する遺伝子操作した細胞ならびにその使用
CN119698467A (zh) 2022-06-08 2025-03-25 世纪治疗股份有限公司 衍生自遗传工程化以具有膜结合的il12的诱导多能干细胞的免疫效应细胞及其用途
EP4544025A1 (en) 2022-06-21 2025-04-30 Institut National de la Santé et de la Recherche Médicale A method for producing a bioengineered mammal induced pluripotent stem cell-derived cardiac organoid
CN119452078A (zh) 2022-06-29 2025-02-14 富士胶片控股美国公司 Ipsc来源的星形胶质细胞及其使用方法
US20240139256A1 (en) 2022-09-30 2024-05-02 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
AU2023375625A1 (en) 2022-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
WO2024192329A1 (en) 2023-03-16 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for producing stable human chondroctyes and their use for promoting cartillage growth and repair
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025245202A1 (en) 2024-05-21 2025-11-27 FUJIFILM Cellular Dynamics, Inc. Particle counting and biomass measurements of aggregated cell compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10113178A (ja) * 1996-09-02 1998-05-06 Gsf Forschungszentrum Fuer Umwelt & Gesundheit Gmbh 遺伝子の条件的発現のためのベクター
JP2007209240A (ja) * 2006-02-08 2007-08-23 National Institute Of Advanced Industrial & Technology 脂質生産性の高い形質転換微生物
WO2008013067A1 (fr) * 2006-07-07 2008-01-31 Kyowa Hakko Kirin Co., Ltd. Vecteur de chromosome artificiel humain (cah), et substance pharmaceutique à base de cellules humaines contenant un vecteur de chromosome artificiel humain (cah)
JP2008067693A (ja) * 2006-08-15 2008-03-27 Ishihara Sangyo Kaisha Ltd 微生物変異体の新規利用方法
WO2009133971A1 (en) * 2008-05-02 2009-11-05 Kyoto University Method of nuclear reprogramming
WO2010028019A2 (en) * 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
ATE398679T1 (de) 1992-07-07 2008-07-15 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
JP2952041B2 (ja) 1992-07-27 1999-09-20 パイオニア ハイ−ブレッド インターナショナル，インコーポレイテッド 培養ダイズ細胞のａｇｒｏｂａｃｔｅｒｉｕｍ媒介形質転換の改良法
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
CA2307807C (en) 1997-10-23 2008-09-02 Andrea G. Bodnar Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US20040199935A1 (en) 1999-06-30 2004-10-07 Chapman Karen B. Cytoplasmic transfer to de-differentiate recipient cells
WO2001096532A2 (en) 2000-06-15 2001-12-20 Tanja Dominko Method of generating pluripotent mammalian cells by fusion of a cytoplast fragment with a karyoplast
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US20020136709A1 (en) 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
US20030044976A1 (en) 2001-08-27 2003-03-06 Advanced Cell Technology De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
JP2004248505A (ja) 2001-09-21 2004-09-09 Norio Nakatsuji 移植抗原の一部または全てを欠除したｅｓ細胞由来の未分化な体細胞融合細胞およびその製造
ITMI20012110A1 (it) 2001-10-12 2003-04-12 Keryos Spa Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico
EP1468094A4 (en) * 2001-12-24 2005-01-26 Es Cell Int Pte Ltd METHOD OF TRANSDUCTING ES CELLS
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0206357D0 (en) * 2002-03-18 2002-05-01 Univ Bath Cells
CA2515108A1 (en) 2003-02-07 2004-08-26 Wisconsin Alumni Research Foundation Directed genetic modifications of human stem cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
KR100484653B1 (ko) 2004-05-06 2005-04-20 주식회사 대웅 원핵세포에서 활성형의 가용성 단백질을 제조하는 방법 및 이를 위한 폴리시스트론 벡터
US7465580B2 (en) * 2004-05-19 2008-12-16 Wisconsin Alumni Research Foundation Non-cytotoxic oriP replicon
AU2005282414C1 (en) 2004-09-08 2011-04-07 Wisconsin Alumni Research Foundation Culturing human embryonic stem cells
US20070087437A1 (en) 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
EP2054079A4 (en) 2006-07-19 2009-12-23 Univ Florida COMPOSITIONS FOR CELL REPROGRAMMING AND USES THEREOF
EP2053128A4 (en) 2006-08-15 2010-05-05 Ishihara Sangyo Kaisha INNOVATIVE METHOD OF USING MICROBIAL MUTANT
US20100069251A1 (en) 2006-09-15 2010-03-18 Children's Medical Center Corporation Methods for producing embryonic stem cells from parthenogenetic embryos
JP5813321B2 (ja) * 2007-03-23 2015-11-17 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
BRPI0810949A2 (pt) 2007-05-29 2015-10-27 Christopher B Reid "método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método"
EP2164951A2 (en) * 2007-05-30 2010-03-24 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009032456A2 (en) * 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
ES2799897T3 (es) 2007-08-31 2020-12-22 Whitehead Inst Biomedical Res Estimulación de la vía wnt en la reprogramación de células somáticas
KR101564044B1 (ko) 2007-10-31 2015-10-28 고쿠리츠 다이가쿠 호진 교토 다이가쿠 핵초기화 방법
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
WO2009067563A1 (en) 2007-11-19 2009-05-28 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (en) * 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
WO2009091543A1 (en) 2008-01-14 2009-07-23 Lindner Scott E An efficient orip/ebna-1 plasmid vector
WO2009092042A1 (en) 2008-01-18 2009-07-23 Nevada Cancer Institute Reprogramming of differentiated progenitor or somatic cells using homologous recombination
WO2009115295A1 (en) * 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
EP3279314A1 (en) 2008-06-04 2018-02-07 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
WO2009157201A1 (en) 2008-06-26 2009-12-30 Osaka University Method and kit for preparing ips cells
WO2010012077A1 (en) 2008-07-28 2010-02-04 Mount Sinai Hospital Compositions, methods and kits for reprogramming somatic cells
CA2734128A1 (en) 2008-08-12 2010-02-18 Cellular Dynamics International, Inc. Methods for the production of ips cells
DK2356221T3 (en) 2008-10-24 2019-02-18 Wisconsin Alumni Res Found Pluripotent stem cells obtained by non-viral reprogramming

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10113178A (ja) * 1996-09-02 1998-05-06 Gsf Forschungszentrum Fuer Umwelt & Gesundheit Gmbh 遺伝子の条件的発現のためのベクター
JP2007209240A (ja) * 2006-02-08 2007-08-23 National Institute Of Advanced Industrial & Technology 脂質生産性の高い形質転換微生物
WO2008013067A1 (fr) * 2006-07-07 2008-01-31 Kyowa Hakko Kirin Co., Ltd. Vecteur de chromosome artificiel humain (cah), et substance pharmaceutique à base de cellules humaines contenant un vecteur de chromosome artificiel humain (cah)
JP2008067693A (ja) * 2006-08-15 2008-03-27 Ishihara Sangyo Kaisha Ltd 微生物変異体の新規利用方法
WO2009133971A1 (en) * 2008-05-02 2009-11-05 Kyoto University Method of nuclear reprogramming
WO2010028019A2 (en) * 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
IN-HYUN PARK, ET AL, NATURE, vol. 451, JPN6015015433, 2007, pages 141 - 147, ISSN: 0003055875 *
MACKEY,D. AND SUGDEN,B.: "The linking regions of EBNA1 are essential for its support of replication and transcription.", MOL. CELL BIOL., vol. 19, no. 5, JPN6013061511, May 1999 (1999-05-01), pages 3349 - 59, XP002526877, ISSN: 0002710450 *
OKITA,K. ET AL.: "Generation of mouse induced pluripotent stem cells without viral vectors.", SCIENCE, vol. 322, no. 5903, JPN6013061515, 7 November 2008 (2008-11-07), pages 949 - 53, XP002571322, ISSN: 0002710453, DOI: 10.1126/science.1164270 *
REN,C. ET AL.: "Establishment and applications of epstein-barr virus-based episomal vectors in human embryonic stem", STEM CELLS, vol. 24, no. 5, JPN6013061508, May 2006 (2006-05-01), pages 1338 - 47, XP009068053, ISSN: 0002710449 *
SEARS,J. ET AL.: "The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate t", J. VIROL., vol. 78, no. 21, JPN6013061513, November 2004 (2004-11-01), pages 11487 - 505, ISSN: 0002710451 *
STADTFELD,M. ET AL.: "Induced pluripotent stem cells generated without viral integration.", SCIENCE, vol. 322, no. 5903, JPN6013061516, 7 November 2008 (2008-11-07), pages 945 - 9, XP002531345, ISSN: 0002710454, DOI: 10.1126/science.1162494 *
THOMSON,J.A. ET AL.: "Embryonic stem cell lines derived from human blastocysts.", SCIENCE, vol. 282, no. 5391, JPN6013061503, 6 November 1998 (1998-11-06), pages 1145 - 7, XP002933311, ISSN: 0002710447, DOI: 10.1126/science.282.5391.1145 *
YU,J. ET AL.: "Human induced pluripotent stem cells free of vector and transgene sequences.", SCIENCE, vol. 324, no. 5928, JPN6013061514, 8 May 2009 (2009-05-08), pages 797 - 801, ISSN: 0002710452 *
YU,J. ET AL.: "Induced pluripotent stem cell lines derived from human somatic cells.", SCIENCE, vol. 318, no. 5858, JPN6013061506, 21 December 2007 (2007-12-21), pages 1917 - 20, XP055435356, ISSN: 0002710448, DOI: 10.1126/science.1151526 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404124B2 (en) 2009-08-07 2016-08-02 Kyoto University Method of producing induced pluripotent stem cells using inhibitors of P53
US10260048B2 (en) 2010-06-15 2019-04-16 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2013176233A1 (ja) * 2012-05-23 2013-11-28 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
JPWO2013176233A1 (ja) * 2012-05-23 2016-01-14 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
US10519425B2 (en) 2012-05-23 2019-12-31 Kyoto University Highly efficient method for establishing induced pluripotent stem cell
JP2019500910A (ja) * 2016-01-12 2019-01-17 ロンザ ウォカーズビル インコーポレーティッド ベクターを含まない人工多能性幹細胞を作製するための方法およびベクター

Also Published As

Publication number Publication date
US20180340150A1 (en) 2018-11-29
IL209740A (en) 2014-01-30
IL209740A0 (en) 2011-02-28
KR20110036548A (ko) 2011-04-07
KR101871192B1 (ko) 2018-06-27
WO2009149233A1 (en) 2009-12-10
EP3279314A1 (en) 2018-02-07
AU2009256202B2 (en) 2014-07-03
JP2020115881A (ja) 2020-08-06
AU2009256202A1 (en) 2009-12-10
CA2954948A1 (en) 2009-12-10
JP2018007667A (ja) 2018-01-18
EP2297307A1 (en) 2011-03-23
US20130189778A1 (en) 2013-07-25
CA2726990A1 (en) 2009-12-10
US9644184B2 (en) 2017-05-09
US20100003757A1 (en) 2010-01-07
JP2018019684A (ja) 2018-02-08
ES2587395T3 (es) 2016-10-24
US20140038293A1 (en) 2014-02-06
EP3447128A1 (en) 2019-02-27
US9328332B2 (en) 2016-05-03
JP2014209912A (ja) 2014-11-13
DK2297307T3 (en) 2016-07-25
KR101648019B1 (ko) 2016-08-16
EP2297307B1 (en) 2016-06-01
CA2726990C (en) 2020-09-08
US8546140B2 (en) 2013-10-01
KR20160025045A (ko) 2016-03-07
EP3112456A1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
JP2020115881A (ja) 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
JP2011522540A5 (https=)
AU2009282133B2 (en) Methods for the Production of IPS Cells
KR20180105670A (ko) 벡터-프리 유도만능 줄기세포를 생성시키기 위한 방법 및 벡터
AU2015255253A1 (en) Methods for the production of ips cells

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150303

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171031

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20171226

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20180124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180131

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180215